Alberto Blanco‐Sánchez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alberto Blanco‐Sánchez has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Joaquín Martínez-López
Hospital 12 de Octubre, i+12, School of Medicine Universidad Complutense, CNIO, Madrid, Spain
5 shared publications - Adolfo Jesús Sáez Marín
Hospital Universitario 12 De Octubre, Madrid
2 shared publications - Rosa Ayala
Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
2 shared publications Adriana Mousa Urbina
Spotlab , P.º de Juan XXIII, 36B, Madrid 28040 , Spain
1 shared publicationAlba Rodríguez-García
Department of Translational Hematology, Research Institute Hospital 12 de Octubre (imas12) , Av. de Córdoba, s/n, Madrid 28041 , Spain
1 shared publicationAlberto Tato
Department of Data Science, Hospital 12 de Octubre, Research Institute Hospital 12 de Octubre Madrid, Spain
1 shared publication
Latest Publications
- 16 September 2026
- Published by Wiley in The Journal of Dermatology
Cutaneous Toxicities of Anti‐ GPRC 5 D Bispecific Antibodies for Multiple Myeloma: Retrospective Study
Talquetamab, a bispecific antibody, has a high efficacy in multiple myeloma (MM), with common dermatologic adverse events. We aim to describe the real‐world burden of cutaneous toxicities. A retrospective study of MM patients treated with talquetamab between March 2021 and February 2026. Demographic and clinical data were extracted from electronic health records. Cutaneous, nail, and mucosal toxicities attributed to talquetamab were recorded. Of 32 patients (mean age 61.4 years; 59.4% male), 28 (87.5%) developed cutaneous adverse events. A total of 87 dermatologic events were recorded. Most frequent manifestations were exanthema (37.5% of cutaneous events), xerosis (33.3%), and palmoplantar involvement (46.9% of patients). Nail toxicity affected 75% of the cohort, predominantly onychomadesis. Mucositis affected 34.4%, with a tendency to occur earlier compared with cutaneous and nail toxicities. Dermatologic evaluation was associated with therapeutic management of adverse events (95.8% vs. 69.9%, p = 0.0098). No patient required permanent talquetamab discontinuation due to mucocutaneous toxicity. Median time to resolution was 50 days. Talquetamab is associated with a high burden of mucocutaneous toxicity. Early dermatologic assessment enables accurate diagnosis and effective management. These findings expand the clinicopathological spectrum of talquetamab toxicity and highlight the importance of interdisciplinary care.
- 16 September 2026
- Published by Wiley in The Journal of Dermatology
Cutaneous Toxicities of Anti‐ GPRC 5 D Bispecific Antibodies for Multiple Myeloma: Retrospective Study
Talquetamab, a bispecific antibody, has a high efficacy in multiple myeloma (MM), with common dermatologic adverse events. We aim to describe the real‐world burden of cutaneous toxicities. A retrospective study of MM patients treated with talquetamab between March 2021 and February 2026. Demographic and clinical data were extracted from electronic health records. Cutaneous, nail, and mucosal toxicities attributed to talquetamab were recorded. Of 32 patients (mean age 61.4 years; 59.4% male), 28 (87.5%) developed cutaneous adverse events. A total of 87 dermatologic events were recorded. Most frequent manifestations were exanthema (37.5% of cutaneous events), xerosis (33.3%), and palmoplantar involvement (46.9% of patients). Nail toxicity affected 75% of the cohort, predominantly onychomadesis. Mucositis affected 34.4%, with a tendency to occur earlier compared with cutaneous and nail toxicities. Dermatologic evaluation was associated with therapeutic management of adverse events (95.8% vs. 69.9%, p = 0.0098). No patient required permanent talquetamab discontinuation due to mucocutaneous toxicity. Median time to resolution was 50 days. Talquetamab is associated with a high burden of mucocutaneous toxicity. Early dermatologic assessment enables accurate diagnosis and effective management. These findings expand the clinicopathological spectrum of talquetamab toxicity and highlight the importance of interdisciplinary care.
- 8 November 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (2) , 106-114.e5
A Large-Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older than 65 Years
- 8 November 2025
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 26 (2) , 106-114.e5
A Large-Scale Analysis of Autologous Stem Cell Transplantation for Multiple Myeloma Patients Older than 65 Years
- Open Access
Long‐Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real‐World Analysis
Introduction: Ruxolitinib is a key therapeutic option for patients with myeloproliferative neoplasms. Its short‐term toxicity profile is well‐established, but long‐term safety data remains scarce. Methods: We aimed to evaluate toxicity associated with long‐term exposure to ruxolitinib (defined as 3 years or longer) through a dual‐cohort retrospective study combining a local cohort from Hospital 12 de Octubre with a large real‐world dataset from TriNetX database. The selected outcomes were non‐melanoma skin cancer (NMSC), other secondary malignancies and infections (zoster, urinary tract infection, pneumonia and sepsis). Results: With a median treatment time of 61.5 months in the local cohort ( n = 36), infections were common (72.2% of patients), with occurrence of late‐onset opportunistic infections such as disseminated mycobacterial disease. A total of 19.4% of patients developed NMSC and 11.1% other secondary malignancies. In the TriNetX cohort, after propensity score matching ( n = 2579), patients with ≥ 3 years of ruxolitinib showed a higher risk of NMSC, zoster, urinary tract infection, pneumonia and sepsis. No significant increase in other tumours was observed. Conclusion: Our findings suggest that extended ruxolitinib therapy is associated with specific long‐term risks, particularly NMSC and zoster reactivation, while not increasing the incidence of secondary malignancies. These results support continued vigilance and preventive strategies in the setting of long‐term ruxolitinib exposure. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission
Open AccessLong‐Term Safety Profile of Ruxolitinib in Chronic Myeloproliferative Neoplasms: A Comprehensive Real‐World Analysis
Introduction: Ruxolitinib is a key therapeutic option for patients with myeloproliferative neoplasms. Its short‐term toxicity profile is well‐established, but long‐term safety data remains scarce. Methods: We aimed to evaluate toxicity associated with long‐term exposure to ruxolitinib (defined as 3 years or longer) through a dual‐cohort retrospective study combining a local cohort from Hospital 12 de Octubre with a large real‐world dataset from TriNetX database. The selected outcomes were non‐melanoma skin cancer (NMSC), other secondary malignancies and infections (zoster, urinary tract infection, pneumonia and sepsis). Results: With a median treatment time of 61.5 months in the local cohort ( n = 36), infections were common (72.2% of patients), with occurrence of late‐onset opportunistic infections such as disseminated mycobacterial disease. A total of 19.4% of patients developed NMSC and 11.1% other secondary malignancies. In the TriNetX cohort, after propensity score matching ( n = 2579), patients with ≥ 3 years of ruxolitinib showed a higher risk of NMSC, zoster, urinary tract infection, pneumonia and sepsis. No significant increase in other tumours was observed. Conclusion: Our findings suggest that extended ruxolitinib therapy is associated with specific long‐term risks, particularly NMSC and zoster reactivation, while not increasing the incidence of secondary malignancies. These results support continued vigilance and preventive strategies in the setting of long‐term ruxolitinib exposure. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission
- Open Access
Real-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre Experience
Despite advances in diagnosis of erythrocytosis and thrombocytosis due to driver mutation testing, many cases remain classified as “idiopathic”. This can be explained by the absence of an evident secondary cause, inconclusive bone marrow biopsy or neglection of family history. Analysis of a broad panel of genes through next-generation sequencing (NGS) could improve diagnostic work-up identifying underlying genetic causes. We reviewed the results of NGS performed in our laboratory and its diagnostic impact on 117 patients with unexplained erythrocytosis and 58 with unexplained thrombocytosis; six patients (5.1%) were diagnosed with polycythaemia vera (PV) and 8 (6.8%) with familial erythrocytosis after NGS testing. Low EPO and a family history seemed to predict a positive result, respectively. However, a greater percentage of patients were ultimately diagnosed with secondary erythrocytosis (36%), remained as idiopathic (28.2%) or were self-limited (15%). The yield of NGS was shown to be slightly higher in patients with thrombocytosis, as 15 (25.9%) were diagnosed with essential thrombocythemia (ET) or familial thrombocytosis after variant detection; previous research has shown similar results, but most of them carried out NGS retrospectively, while the present study exhibits the performance of this test in a real-world setting. Overall, the low rate of variant detection and its poor impact on diagnostic work-up highlights the need for a thorough screening prior to NGS, in order to improve its yield.
Open AccessReal-World Impact of Deep Targeted Sequencing on Erythrocytosis and Thrombocytosis Diagnosis: A Reference Centre Experience
Despite advances in diagnosis of erythrocytosis and thrombocytosis due to driver mutation testing, many cases remain classified as “idiopathic”. This can be explained by the absence of an evident secondary cause, inconclusive bone marrow biopsy or neglection of family history. Analysis of a broad panel of genes through next-generation sequencing (NGS) could improve diagnostic work-up identifying underlying genetic causes. We reviewed the results of NGS performed in our laboratory and its diagnostic impact on 117 patients with unexplained erythrocytosis and 58 with unexplained thrombocytosis; six patients (5.1%) were diagnosed with polycythaemia vera (PV) and 8 (6.8%) with familial erythrocytosis after NGS testing. Low EPO and a family history seemed to predict a positive result, respectively. However, a greater percentage of patients were ultimately diagnosed with secondary erythrocytosis (36%), remained as idiopathic (28.2%) or were self-limited (15%). The yield of NGS was shown to be slightly higher in patients with thrombocytosis, as 15 (25.9%) were diagnosed with essential thrombocythemia (ET) or familial thrombocytosis after variant detection; previous research has shown similar results, but most of them carried out NGS retrospectively, while the present study exhibits the performance of this test in a real-world setting. Overall, the low rate of variant detection and its poor impact on diagnostic work-up highlights the need for a thorough screening prior to NGS, in order to improve its yield.
- Open Access
- 1 February 2024
- Published by Oxford University Press (OUP) in Microscopy and Microanalysis
- Vol. 30 (1) , 151-159
Digital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases
Analysis of bone marrow aspirates (BMAs) is an essential step in the diagnosis of hematological disorders. This analysis is usually performed based on a visual examination of samples under a conventional optical microscope, which involves a labor-intensive process, limited by clinical experience and subject to high observer variability. In this work, we present a comprehensive digital microscopy system that enables BMA analysis for cell type counting and differentiation in an efficient and objective manner. This system not only provides an accessible and simple method to digitize, store, and analyze BMA samples remotely but is also supported by an Artificial Intelligence (AI) pipeline that accelerates the differential cell counting process and reduces interobserver variability. It has been designed to integrate AI algorithms with the daily clinical routine and can be used in any regular hospital workflow.
- 1 February 2024
- Published by Oxford University Press (OUP) in Microscopy and Microanalysis
- Vol. 30 (1) , 151-159
Open AccessDigital Microscopy Augmented by Artificial Intelligence to Interpret Bone Marrow Samples for Hematological Diseases
Analysis of bone marrow aspirates (BMAs) is an essential step in the diagnosis of hematological disorders. This analysis is usually performed based on a visual examination of samples under a conventional optical microscope, which involves a labor-intensive process, limited by clinical experience and subject to high observer variability. In this work, we present a comprehensive digital microscopy system that enables BMA analysis for cell type counting and differentiation in an efficient and objective manner. This system not only provides an accessible and simple method to digitize, store, and analyze BMA samples remotely but is also supported by an Artificial Intelligence (AI) pipeline that accelerates the differential cell counting process and reduces interobserver variability. It has been designed to integrate AI algorithms with the daily clinical routine and can be used in any regular hospital workflow.